| 000 | 01299 a2200373 4500 | ||
|---|---|---|---|
| 005 | 20250515042021.0 | ||
| 264 | 0 | _c20061205 | |
| 008 | 200612s 0 0 eng d | ||
| 022 | _a0887-6924 | ||
| 024 | 7 |
_a10.1038/sj.leu.2404398 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMesa, R A | |
| 245 | 0 | 0 |
_aHematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. _h[electronic resource] |
| 260 |
_bLeukemia _cNov 2006 |
||
| 300 |
_a2063-4 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Letter | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aChromosome Deletion |
| 650 | 0 | 4 | _aChromosomes, Human, Pair 5 |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aJanus Kinase 2 _xgenetics |
| 650 | 0 | 4 | _aLenalidomide |
| 650 | 0 | 4 |
_aLeukemia, Myeloid _xdrug therapy |
| 650 | 0 | 4 |
_aMyelodysplastic Syndromes _xcomplications |
| 650 | 0 | 4 | _aPoint Mutation |
| 650 | 0 | 4 |
_aThalidomide _xanalogs & derivatives |
| 700 | 1 | _aTefferi, A | |
| 700 | 1 | _aLi, C-Yang | |
| 700 | 1 | _aSteensma, D P | |
| 773 | 0 |
_tLeukemia _gvol. 20 _gno. 11 _gp. 2063-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.leu.2404398 _zAvailable from publisher's website |
| 999 |
_c16569327 _d16569327 |
||